NasdaqGS:GRALBiotechs
GRAIL (GRAL) Is Up 6.0% After Strong SYMPLIFY Data and Samsung Partnership – Has Its Commercial Path Shifted?
GRAIL, Inc. announced positive long-term clinical trial results for its Galleri multi-cancer early detection blood test and secured approximately US$325 million in new private funding, including a US$110 million investment and partnership deal with Samsung to bring Galleri to key Asian markets.
Follow-up data from the SYMPLIFY study showed the Galleri test’s positive predictive value increased to 84.2%, highlighting its potential to improve cancer detection in symptomatic individuals through...